Walleye Capital LLC cut its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) by 45.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 218,917 shares of the biopharmaceutical company’s stock after selling 184,202 shares during the quarter. Walleye Capital LLC’s holdings in Puma Biotechnology were worth $630,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of PBYI. Rice Hall James & Associates LLC lifted its position in shares of Puma Biotechnology by 4.1% in the first quarter. Rice Hall James & Associates LLC now owns 511,233 shares of the biopharmaceutical company’s stock valued at $1,472,000 after acquiring an additional 19,951 shares in the last quarter. Mirabella Financial Services LLP purchased a new position in Puma Biotechnology in the 1st quarter valued at $73,000. Western Standard LLC acquired a new stake in Puma Biotechnology during the 1st quarter worth $334,000. State Street Corp grew its holdings in shares of Puma Biotechnology by 10.6% during the first quarter. State Street Corp now owns 639,629 shares of the biopharmaceutical company’s stock worth $1,842,000 after buying an additional 61,539 shares in the last quarter. Finally, Eversept Partners LP lifted its stake in shares of Puma Biotechnology by 27.4% in the first quarter. Eversept Partners LP now owns 1,424,650 shares of the biopharmaceutical company’s stock worth $4,103,000 after buying an additional 306,752 shares in the last quarter. 62.26% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Michael Patrick Miller sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $3.55, for a total value of $88,750.00. Following the completion of the transaction, the director now directly owns 54,858 shares in the company, valued at $194,745.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Alan H. Auerbach sold 26,140 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $2.63, for a total value of $68,748.20. Following the sale, the chief executive officer now directly owns 6,317,952 shares of the company’s stock, valued at approximately $16,616,213.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Patrick Miller sold 25,000 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $3.55, for a total transaction of $88,750.00. Following the completion of the sale, the director now owns 54,858 shares of the company’s stock, valued at approximately $194,745.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,565 shares of company stock valued at $188,024. 21.20% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Puma Biotechnology Stock Performance
NASDAQ:PBYI opened at $2.46 on Thursday. The company’s 50-day moving average is $3.00 and its two-hundred day moving average is $2.75. Puma Biotechnology, Inc. has a 1-year low of $1.60 and a 1-year high of $7.73. The company has a debt-to-equity ratio of 4.95, a current ratio of 2.01 and a quick ratio of 1.89. The firm has a market capitalization of $112.07 million, a price-to-earnings ratio of -2.86 and a beta of 0.67.
Puma Biotechnology Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.
- Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.